Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Inventory (2017 - 2025)

Ptc Therapeutics has reported Inventory over the past 9 years, most recently at $79.6 million for Q4 2025.

  • Quarterly results put Inventory at $79.6 million for Q4 2025, up 243.39% from a year ago — trailing twelve months through Dec 2025 was $79.6 million (up 243.39% YoY), and the annual figure for FY2025 was $79.6 million, up 243.39%.
  • Inventory for Q4 2025 was $79.6 million at Ptc Therapeutics, up from $52.7 million in the prior quarter.
  • Over the last five years, Inventory for PTCT hit a ceiling of $79.6 million in Q4 2025 and a floor of $14.8 million in Q3 2022.
  • Median Inventory over the past 5 years was $24.9 million (2023), compared with a mean of $28.2 million.
  • Peak annual rise in Inventory hit 243.39% in 2025, while the deepest fall reached 27.89% in 2025.
  • Ptc Therapeutics' Inventory stood at $15.9 million in 2021, then surged by 37.54% to $21.8 million in 2022, then soared by 40.21% to $30.6 million in 2023, then fell by 24.15% to $23.2 million in 2024, then surged by 243.39% to $79.6 million in 2025.
  • The last three reported values for Inventory were $79.6 million (Q4 2025), $52.7 million (Q3 2025), and $34.1 million (Q2 2025) per Business Quant data.